Earnings summaries and quarterly performance for SOLIGENIX.
Executive leadership at SOLIGENIX.
Christopher Schaber
Detailed
Chief Executive Officer and President
CEO
JG
Jonathan Guarino
Detailed
Chief Financial Officer, Senior Vice President and Corporate Secretary
OD
Oreola Donini
Detailed
Chief Scientific Officer and Senior Vice President
RS
Richard Straube
Detailed
Chief Medical Officer and Senior Vice President
Board of directors at SOLIGENIX.
Research analysts covering SOLIGENIX.
Recent press releases and 8-K filings for SNGX.
Soligenix Enters At Market Issuance Sales Agreement
SNGX
- Soligenix, Inc. entered into an At Market Issuance Sales Agreement with Rodman & Renshaw LLC on January 23, 2026.
- This agreement allows Soligenix to sell shares of its common stock with an aggregate offering price of up to $3,450,000 through Rodman & Renshaw as a sales agent.
- Rodman & Renshaw will receive a commission rate of up to 3.0% of the gross proceeds from the sale of shares.
- The offering is scheduled to terminate by the earliest of December 15, 2026, the sale of all shares, or termination by either party.
Jan 23, 2026, 9:05 PM
Soligenix Announces Publication of Positive Phase 2a Clinical Results for SGX945 in Behçet's Disease
SNGX
New Projects/Investments
- Soligenix announced the publication of positive results from its Phase 2a proof of concept study evaluating SGX945 (dusquetide) for the treatment of Behçet's Disease in Rheumatology (Oxford).
- The study reported beneficial effects for 7 of 8 patients, with SGX945 demonstrating a 40% improvement in the area under the curve (AUC) of oral ulcers after 4 weeks of treatment, which was sustained with 32% improvement at Week 8 even after treatment cessation at Week 4.
- SGX945 was well-tolerated with no treatment-related adverse events, in contrast to apremilast which had common adverse events including diarrhea (41%), nausea (19%), and headache (14%).
- Soligenix intends to reformulate SGX945 for home-based subcutaneous injection and expand its development into other innate immune-related inflammatory conditions, addressing an unmet medical need for Behçet's Disease, which affects up to 1 million people worldwide.
Dec 18, 2025, 12:30 PM
Soligenix Announces Positive Phase 2a Results for SGX302 in Psoriasis
SNGX
New Projects/Investments
- Soligenix, Inc. announced positive extended results from its ongoing Phase 2a trial of SGX302 (synthetic hypericin) for the treatment of mild-to-moderate psoriasis, utilizing an optimized gel formulation.
- The SGX302 gel therapy was well tolerated by all patients with no drug-related adverse events identified, and evaluable patients demonstrated improvements across multiple indices, including the Investigator Global Assessment (IGA) and Psoriasis Activity and Severity Index (PASI).
- One patient in Cohort 3 achieved a disease status of "Almost Clear" using the IGA, with a substantial improvement in their PASI score, exceeding 50%.
- The global psoriasis treatment market was valued at approximately $15 billion in 2020 and is projected to reach as much as $40 billion by 2027.
- Soligenix anticipates continuing to pursue SGX302 in psoriasis as it advances the confirmatory Phase 3 trial for HyBryte™ in cutaneous T-cell lymphoma (CTCL), with topline results for HyBryte™ expected in the second half of 2026.
Dec 17, 2025, 12:30 PM
Soligenix Advances HyBryte for Cutaneous T-Cell Lymphoma
SNGX
New Projects/Investments
Product Launch
- Soligenix Inc. (SNGX), a late-stage biopharmaceutical company, is conducting the final confirmatory clinical study for HyBryte[TM] (synthetic hypericin), a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL), before seeking worldwide marketing approval.
- The company's Specialized BioTherapeutics segment also includes development programs for psoriasis, inflammatory diseases, and Behçet’s disease.
- Soligenix's Public Health Solutions segment focuses on vaccine candidates for ricin toxin, filoviruses, and COVID-19, with development supported by government grants and contract funding.
Dec 10, 2025, 1:30 PM
Soligenix Achieves Enrollment Milestone for HyBryte™ Phase 3 Clinical Trial
SNGX
New Projects/Investments
- Soligenix has completed the enrollment of 50 patients necessary for the interim analysis in its 80-patient confirmatory Phase 3 FLASH2 study evaluating HyBryte™ for the treatment of cutaneous T-cell lymphoma (CTCL).
- The planned interim analysis for the FLASH2 study is expected in the second quarter of 2026, with topline results anticipated in the second half of 2026.
- The overall blinded study response rate to date for FLASH2 is 48%, exceeding the trial's anticipated overall blinded study response rate of 25%.
- HyBryte™ has received orphan drug and fast track designations from the FDA, and orphan designation from the European Medicines Agency (EMA).
Nov 19, 2025, 12:30 PM
Soligenix announces Q3 2025 financial results and clinical trial updates
SNGX
Earnings
New Projects/Investments
Guidance Update
- Soligenix reported no revenue for the quarter ended September 30, 2025, with a net loss of $2.5 million, or ($0.58) per share.
- The company's cash position was approximately $10.5 million as of September 30, 2025, which is expected to provide an operating runway through 2026.
- Key clinical milestones include the conclusion of the first Data Monitoring Committee meeting for the confirmatory Phase 3 study of HyBryte™ in CTCL with no safety concerns, and anticipated top-line results for the Phase 2a clinical trial of SGX302 in psoriasis before year-end.
- Top-line results for the confirmatory Phase 3 study of HyBryte™ in CTCL are anticipated in the second half of 2026.
Nov 7, 2025, 12:30 PM
Sotera Health Company Reports Strong Q3 2025 Results and Raises Full-Year Outlook
SNGX
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Sotera Health Company reported Q3 2025 net revenues of $311 million, an increase of 9.1% compared to Q3 2024, with net income of $48 million (or $0.17 per diluted share) and Adjusted EBITDA of $164 million, up 12.2%. Adjusted EPS for Q3 2025 was $0.26.
- For the first nine months of 2025, net revenues increased 6.2% to $860 million, and Adjusted EBITDA grew 10.4% to $437 million compared to the same period in 2024.
- The company raised its 2025 Adjusted EBITDA growth range to 6.75% - 7.75% and Adjusted EPS range to $0.81 to $0.86, while reaffirming its net revenues outlook of 4.5% - 6.0% on a constant currency basis.
- As of September 30, 2025, Sotera Health had $2.2 billion of total debt and $299 million in unrestricted cash, with its Net Leverage Ratio improving to 3.3x from 3.7x as of December 31, 2024.
Nov 4, 2025, 12:00 PM
Soligenix Announces Closing of Public Offering
SNGX
- Soligenix, Inc. announced the closing of a public offering on September 29, 2025, generating approximately $7.5 million in gross proceeds.
- The offering involved the sale of 5,555,560 shares of common stock (or common stock equivalents) and warrants to purchase up to 5,555,560 shares of common stock, at a combined purchase price of $1.35 per share and accompanying warrant.
- This funding is expected to extend the company's cash runway through the end of 2026 and will be used for research and development, commercialization activities, working capital, and general corporate purposes.
- Additionally, certain existing warrants to purchase 1,162,064 shares were amended to have a reduced exercise price of $1.35 per share and will expire commensurate with the warrants sold in the offering.
Sep 29, 2025, 8:22 PM
Soligenix Announces Closing of Public Offering
SNGX
New Projects/Investments
Guidance Update
- Soligenix, Inc. has closed a public offering, generating approximately $7.5 million in aggregate gross proceeds.
- The offering involved the sale of 5,555,560 shares of common stock (or equivalents) and warrants to purchase up to 5,555,560 shares of common stock at a combined purchase price of $1.35 per share and accompanying warrant.
- This funding is expected to extend the Company's cash runway through the end of 2026.
- Proceeds from the offering are intended to fund research and development, commercialization activities, working capital, and general corporate purposes.
Sep 29, 2025, 8:05 PM
Soligenix Prices Public Offering
SNGX
New Projects/Investments
- Soligenix, Inc. (SNGX) announced the pricing of a "reasonable best efforts" public offering with existing and certain healthcare focused institutional investors.
- The offering includes 5,555,560 shares of common stock (or equivalents) and warrants to purchase up to 5,555,560 shares of common stock at a combined purchase price of $1.35 per share and accompanying warrant.
- The gross proceeds from the offering are expected to be approximately $7.5 million, with net proceeds intended to fund research and development, commercialization activities, working capital, and general corporate purposes.
- The company also agreed to amend certain existing warrants for 1,162,064 shares to reduce their exercise price to $1.35 per share.
- The closing of the offering is expected to occur on or about September 29, 2025.
Sep 26, 2025, 10:33 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more